Thu, Sep 18, 2014, 7:24 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • formerblueguy formerblueguy Dec 26, 2012 8:17 AM Flag

    New seeking alpha article

    Has Nviv roaring next year....let's hope it's a lion's ROAR,,
    Happy New Year to all...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Don't think the article is correct that FDA approved HUD pathway yet... Unless author privy to info we don't have. Nviv just applied for HUD status no?

      • 2 Replies to formerblueguy
      • Hmmmm check out the comments at the end of the SA article. Author indicates that Frank said company has received FDA approval.... Whether true or false -- sounds like the Nviv way of doing PR. Of course, hoping it is true.

      • write2fran@sbcglobal.net write2fran Dec 26, 2012 9:17 AM Flag

        This is what I copied from press release dated december 14, 2012.....

        the Company has filed a request with the U.S. Food and Drug Administration (FDA) for Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product. InVivo is currently working with the FDA on the final steps to seek approval to begin a clinical trial of the scaffolding in acute SCI in early 2013.

        looks like just a request so far...approval probably not far away...jmo

        Sentiment: Buy

    • Following this stock has blurred my vision as below I apologized for thinking the Japanese Symposium for (drug delivery systems) had taken place in 2009. I was wrong as it will be held in January of 2013. The article was taken from the Langer Lab page of MIT News.

      The 12th US-Japan Symposium on Drug Delivery Systems Conference will be held on Monday, December 16 to Friday, December 20, 2013.

      The Symposium is co-sponsored by the Japanese Society of Drug Delivery Systems, the Massachusetts Institute of Technology, and Kyoto University.

      The symposium offers presentations by researchers from a number of disciplines, from the life sciences to engineering, who will address a range of topics including peptide and protein delivery, gene delivery, cell delivery, vaccines, transdermals, pulmonary delivery, new materials, and other subjects, from varied disciplines while focusing on the central theme of drug delivery. The Symposium offers a unique opportunity for interaction and networking among attendees from academia and industry.

      Sentiment: Hold

 
NVIV
0.50-0.02(-3.85%)Sep 18 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.